Galeterone is a steroid 17-α-hydroxylase/17,20 lyase and androgen receptor antagonist intended for patients with prostate cancer. Similar to abiraterone, galeterone has a steroid scaffold structure and mimics natural ligands; thus, these agents are metabolized by the same enzymes that synthesize or degrade naturally occurring steroids, which can result in attenuated efficacy.
Refers to Alyamani, M. et al. Steroidogenic metabolism of galeterone reveals a diversity of biochemical activities. Cell Chem. Biol.24, 825-832.e6 (2017)